BioCentury
ARTICLE | Clinical News

Laquinimod meets Crohn's endpoints

October 23, 2012 1:07 AM UTC

Active Biotech AB (SSE:ACTI) gained SEK2.50 to SEK63.40 on Monday after it and Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported data from a Phase IIa trial of oral laquinimod to treat moderate to severe Crohn's disease (CD). Once-daily, 0.5 mg doses of the oral quinoline-3-carboxamide immunomodulator improved remission (48.3% vs. 15.9%) and response (62.1% vs. 34.9%) rates vs. placebo. Patients received placebo or once-daily laquinimod for 8 weeks with 4 weeks of follow-up. Active Biotech and Teva could not be reached for details. The partners said they are analyzing the data to finalize next steps, which include Phase II/III testing. ...